gefitinib has been researched along with Cicatrix in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, PC; Chu, CY; Shih, YH | 1 |
Donovan, JC; Ghazarian, DM; Shaw, JC | 1 |
2 other study(ies) available for gefitinib and Cicatrix
Article | Year |
---|---|
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
Topics: Aged; Alopecia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cicatrix; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Risk Assessment; Severity of Illness Index | 2013 |
Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cicatrix; Disease Progression; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Risk Assessment | 2008 |